Physician profile
Warren A Marks
NPI 1285727370
$58,201.00
in general payments reported to CMS, 2019-2025
17 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,710 · 2020: $15K · 2021: $5,024 · 2022: $18K · 2023: $5,641 · 2024: $5,503 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,726 · Food and Beverage: $2,542 · Travel and Lodging: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,725.50 |
| Food and Beverage | $2,541.95 |
| Travel and Lodging | $2,087.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $21,877.67 | 2020-2025 | |
| Ptc Therapeutics, INC. | $19,410.65 | 2019-2024 | |
| Catalyst Pharmaceuticals, INC. | $4,866.20 | 2024 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $4,529.50 | 2020-2023 | Zolgensma |
| Genentech USA, INC. | $3,973.82 | 2019 | |
| Neurocrine Biosciences, INC. | $1,480.14 | 2022-2023 | |
| Genentech, INC. | $904.96 | 2023 | Evrysdi |
| Ipsen Biopharmaceuticals, INC | $294.90 | 2022-2023 | Dysport |
| Ucb, INC. | $224.56 | 2022-2025 | Briviact |
| Biogen, INC. | $151.85 | 2024 | Spinraza, Skyclarys |
| Greenwich Biosciences, INC. | $125.79 | 2019 | |
| Medtronic USA, INC. | $125.38 | 2019 | |
| Biomarin Pharmaceutical INC. | $118.64 | 2023 | Brineura |
| Orthopediatrics Corp. | $75.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.14 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itf Therapeutics LLC | $16.84 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.